- The non-negotiable questions to ask at a relapse consultation
- What oligometastatic disease is — and why it's clinically distinct from widely metastatic disease
- The SABR-COMET trial results and what they mean for patients with limited-site metastasis
- How platinum sensitivity/resistance determines second-line options in ovarian cancer
- Why re-biopsy and molecular profiling are essential before committing to second-line therapy
The consultation at which relapse is confirmed is one of the most emotionally difficult medical appointments a cancer patient faces. It is also one of the most information-dense. The risk is that emotional shock prevents the patient from hearing, remembering, or asking what needs to be heard, remembered, and asked. This chapter is preparation for that conversation.
Questions to Ask at the Relapse Consultation
- "Can we confirm this is true relapse rather than a scan artifact or another cause? What imaging/biopsy confirms this?"
- "Is re-biopsy recommended? How similar or different might the molecular profile be from the original?"
- "Are there clinical trials I'm currently eligible for? Even Phase I or Phase II?"
- "What is the treatment goal at this point — curative intent, long-term disease control, or symptom management? These require different strategies."
- "What are the two or three most realistic treatment options? What does the evidence say about each?"
- "How will we know if the chosen treatment is working — and at what point would we reassess?"
- "Is this a situation where a second opinion from a major cancer center would change our options?"
- "What is the expected impact on quality of life during treatment? What can be done to minimize it?"
Relapsed cancer has often evolved its molecular profile. In NSCLC, HER2+ breast cancer, and ovarian cancer, the treatment targets at relapse may be entirely different from those at initial diagnosis — HER2 status can flip, BRCA reversion mutations can emerge, immune checkpoint expression can change. Treating based on the original biopsy profile risks treating the wrong target. Before committing to second-line therapy, confirm with your oncologist whether the relapse site is biopsied or re-profiled.
Oligometastatic Disease — A Distinct and Treatable Category
Oligometastatic disease refers to limited metastatic spread — typically 1–5 lesions in 1–3 organs. It is increasingly recognized as clinically distinct from widespread metastatic disease and may be treatable with curative or long-term control intent rather than purely palliative intent.
| Feature | Oligometastatic | Polymetastatic (Widely Disseminated) |
|---|---|---|
| Lesion count | Typically 1–5 | Multiple, often uncountable |
| Organ involvement | 1–3 organs | Often multiple organ systems |
| Treatment approach | May include ablative local therapy (SBRT, surgery, RFA) to each lesion | Systemic therapy — chemotherapy, targeted, or immunotherapy — is the primary approach |
| Potential outcome | Long-term disease control; occasionally cure | Disease stabilization and symptom management |
| Key criterion | Systemic disease well-controlled between lesions; primary tumor controlled | Active disease beyond countable lesions |
The SABR-COMET Trial
The SABR-COMET randomized controlled trial (published in JAMA, 2019; updated data 2023) is the landmark study that established the evidence basis for ablative radiation (SABR/SBRT) in oligometastatic disease. Key findings:
| Outcome | Control Arm (Palliative Standard Care) | SABR Arm (Stereotactic Ablative Radiotherapy) |
|---|---|---|
| 5-year overall survival | 17.7% | 42.3% |
| Progression-free survival (median) | 3.5 months | 12 months |
| Grade 2–4 toxicity | 9% | 30% |
| Patient eligibility | 1–5 active metastatic lesions, controlled primary, good performance status (ECOG 0–1), radical treatment of all lesions feasible | |
Platinum Sensitivity and Resistance — Ovarian Cancer
Platinum-based chemotherapy (carboplatin, cisplatin) is central to ovarian cancer treatment. At relapse, the treatment decision pivots heavily on platinum sensitivity — defined by the interval between last platinum therapy and relapse:
| Category | Definition | Typical Treatment Approach |
|---|---|---|
| Platinum-sensitive | Relapse >6 months after last platinum | Re-challenge with platinum-based doublet (carboplatin + paclitaxel, or carboplatin + gemcitabine); PARP inhibitor maintenance if BRCA mutation or HRD positive |
| Partially platinum-sensitive | Relapse 6–12 months after last platinum | Platinum re-challenge still considered; individual assessment required; bevacizumab combination data supports |
| Platinum-resistant | Relapse <6 months after last platinum | Non-platinum single agents (liposomal doxorubicin, topotecan, gemcitabine, weekly paclitaxel ± bevacizumab); clinical trials strongly preferred |
| Platinum-refractory | Progression during active platinum therapy | Non-platinum therapy; early clinical trial consideration; immunotherapy evaluation if MSI-H or TMB-high |
For ovarian cancer specifically, also ask about BRCA mutation testing (germline and somatic) if not already done — this determines eligibility for PARP inhibitors (olaparib, niraparib, rucaparib), which have shown significant progression-free survival benefit in BRCA-mutant recurrent ovarian cancer.
Second Opinion at Relapse — When It's Worth It
A second opinion from a major cancer center (NCI-designated or equivalent) is particularly valuable at relapse when:
- The tumor is rare, the histology is unusual, or the molecular profile is complex
- No clinical trial is available at the local center but the patient wants to explore enrollment
- The oncologist's recommendation involves a regimen with significant uncertainty about efficacy in this specific context
- Oligometastatic disease is suspected — ablative options may require specialist evaluation
- Prepare eight specific questions before the relapse consultation — the emotional shock of the appointment makes unprepared engagement almost impossible.
- Re-biopsy and molecular re-profiling at relapse are strongly recommended — the tumor's targetable characteristics may have changed completely since initial diagnosis.
- Oligometastatic disease (1–5 lesions in 1–3 organs) may be treatable with ablative intent using SBRT. The SABR-COMET trial demonstrated 42.3% vs. 17.7% 5-year survival — a transformative difference.
- In ovarian cancer, platinum sensitivity interval determines second-line treatment strategy more than any other single factor. Know whether the relapse is platinum-sensitive, resistant, or refractory before the treatment conversation.